Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: ccryder who wrote (776)	5/15/2000 10:32:00 AM
From: opalapril	Read Replies (1) \| Respond to of 834

Texas Biotechnology Announces First Quarter Financial Results and Updates Shareholders on Key Corporate Programs Net Loss Increases Due to Initiation of Phase II Pulmonary Hypertension Clinical Trial for Sitaxsentan and Pre-Marketing Programs for NOVASTAN(R) (Argatroban) Submits Complete Response to the U.S. FDA Approvable Letter for NOVASTAN * * * "TBC announced that it has submitted its response to the approvable letter for NOVASTAN issued by the U.S. Food & Drug Administration on February 18, 2000. The approvable letter from FDA included the Agency's recommendation for NOVASTAN as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). Based on recent discussions with representatives from FDA, TBC expects a response from the Agency by mid July." biz.yahoo.com